Mackenzie Financial
LYEL icon

Mackenzie Financial’s Lyell Immunopharma LYEL Stock Holding History

Mackenzie Financial’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-560
Closed -$6.03K – 1768
2025
Q1 		$6.03K Hold
560
– – ﹤0.01% 1666
2024
Q4 		$7.17K Hold
560
– – ﹤0.01% 1690
2024
Q3 		$15.5K Hold
560
– – ﹤0.01% 1571
2024
Q2 		$16.2K Hold
560
– – ﹤0.01% 1521
2024
Q1 		$25K Hold
560
– – ﹤0.01% 1505
2023
Q4 		$21.7K Hold
560
– – ﹤0.01% 1482
2023
Q3 		$16.1K Hold
560
– – ﹤0.01% 1460
2023
Q2 		$34.7K Hold
560
– – ﹤0.01% 1479
2023
Q1 		$26.4K Hold
560
– – ﹤0.01% 1474
2022
Q4 		$38.9K Hold
560
– – ﹤0.01% 1373
2022
Q3 		$82K Sell
560
-30
-5% -$4.06K ﹤0.01% 1322
2022
Q2 		$77K Buy
+590
New +$60.3K ﹤0.01% 1361

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return